The goals of his translational research program are to investigate the cellular and molecular mechanisms underlying major depressive disorders (MDD), normal aging or pathological aging, and their respective interactions and, to use this knowledge to develop strategies for novel therapeutic approaches. To reach these goals, he employs interdisciplinary approaches to characterize the primary pathology in animal models, confirm its relevance in human database, and identify new avenues for therapeutic development. Then, combining his expertise in behavioral neuropsychopharmacology with computational approaches, chemistry, genetic or imaging through highly collaborative efforts, he uses preclinical models to develop treatment strategies with translational potential that can have an impact on societal mental health. His work is highly translational by nature, as he is now working at the interface between basic neuroscience identifying underlying mechanisms involved in psychiatric pathologies, and the pharmaceutical environment looking for the development of novel therapies to alleviate the burden caused by psychiatric disorders.